Abstract
There is limited treatment options for patients with metastatic or recurrent cervical cancer who progressed after standard first-line chemotherapy. Recently, immune checkpoint inhibitor (ICI) therapy has been approved as a second-line treatment for patients with advanced cervical cancer. However, only a small subset of patients responds to ICI therapy. ICI therapy combined with anti-angiogenic drugs may enhance cancer immunity and is a promising option for advanced cervical cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
